Page 15 - hypertension_newsletter7
P. 15
REFLECTIONS
Hypertension
Hypertension Global Newsletter #7 2024
Beyond weight loss, the authors summarise that these AOMs have improved on SBP and LDL-C (see summary table below).
Weight and CV risk factor outcomes of antiobesity medications
Hypertension
in adults with obesity and without diabetes by mechanism of action
As many patients with obesity also suffer from comorbidities, the authors summarise some of the considerations for using these
AOMs in specific patient populations to individualise selection (see table below). In particular, some of the AOMs have been
shown to lower BP and may be advantageous in patients with comorbid hypertension. Others may have limited data or are
recommended to be used with caution in special populations. The authors also give some additional practical considerations in
prescribing and managing antiobesity medications for each approved medication.
TABLE OF CONTENTS
